Racura Oncology Ltd (ASX:RAC)

Market Cap	516.39M +151.9%
Revenue (ttm)	3.48M -46.1%
Net Income	-9.39M
EPS	-0.05
Shares Out	187.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,486
Average Volume	217,447
Open	2.740
Previous Close	2.760
Day's Range	2.610 - 2.750
52-Week Range	1.115 - 4.900
Beta	0.84
RSI	52.79
Earnings Date	May 28, 2026

About Racura Oncology

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In fiscal year 2025, Racura Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.